

A First-in-Human Study and Biomarker Analysis of NK7 Patients with Advanced or Metastatic Solid Tumors

Cancer Discovery

9, 711-721

DOI: [10.1158/2159-8290.cd-18-1495](https://doi.org/10.1158/2159-8290.cd-18-1495)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytokine Therapeutics in Cancer Immunotherapy: Design and Development. <i>Current Pharmacology Reports</i> , 2019, 5, 377-390.	1.5	4
2	Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. <i>Cancers</i> , 2019, 11, 1040.	1.7	40
3	Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1223-1228.	1.4	17
4	Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience. <i>Seminars in Immunology</i> , 2019, 44, 101325.	2.7	30
5	Smart cancer nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 1007-1017.	15.6	776
6	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2019, 59, 290-297.	4.3	78
7	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 89.	6.9	33
8	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5
9	Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era. <i>Cancer Discovery</i> , 2019, 9, 694-695.	7.7	10
10	Combination Immunotherapy Strategies in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 228-240.	0.5	5
11	The landscape of immunotherapy in metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2019, 29, 643-648.	0.9	5
12	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. <i>Cancers</i> , 2020, 12, 99.	1.7	23
13	Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice. <i>Journal of Controlled Release</i> , 2020, 317, 282-290.	4.8	3
14	The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. <i>Nature Immunology</i> , 2020, 21, 835-847.	7.0	243
15	Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3586.	1.7	75
16	Natural killer cells in cancer biology and therapy. <i>Molecular Cancer</i> , 2020, 19, 120.	7.9	344
17	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	1.1	20
18	Pegylated Engineered IL2 plus Anti–PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. <i>Cancer Discovery</i> , 2020, 10, 1097-1099.	7.7	7

#	ARTICLE	IF	CITATIONS
19	Therapeutic strategies to remodel immunologically cold tumors. <i>Clinical and Translational Immunology</i> , 2020, 9, e1226.	1.7	23
20	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. <i>Karger Kompass Dermatologie</i> , 2020, 8, 92-101.	0.0	0
21	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+T cell responses capable of curing multi-focal cancer. , 2020, 8, e000464.		20
22	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
23	The future of cancer immunotherapy: microenvironment-targeting combinations. <i>Cell Research</i> , 2020, 30, 507-519.	5.7	480
24	Cytokines that target immune killer cells against tumors. <i>Cellular and Molecular Immunology</i> , 2020, 17, 722-727.	4.8	20
25	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
26	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolimmunology</i> , 2020, 9, 1771143.	2.1	116
27	Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy. <i>Current Oncology Reports</i> , 2020, 22, 38.	1.8	15
28	Current progress in NK cell biology and NK cell-based cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 879-899.	2.0	33
29	Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 251-266.	12.5	408
30	Dedifferentiated Liposarcoma: Systemic Therapy Options. <i>Current Treatment Options in Oncology</i> , 2020, 21, 15.	1.3	46
31	A universal reporter cell line for bioactivity evaluation of engineered cytokine products. <i>Scientific Reports</i> , 2020, 10, 3234.	1.6	10
32	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	1.0	95
33	Enhancing cancer immunotherapy with nanomedicine. <i>Nature Reviews Immunology</i> , 2020, 20, 321-334.	10.6	506
34	Exploiting Human NK Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 3013.	2.2	37
35	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127
36	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. <i>Nature Communications</i> , 2020, 11, 660.	5.8	68

#	ARTICLE	IF	CITATIONS
37	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	5.8	124
38	The Promise of Combining Radiation Therapy With Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 6-16.	0.4	92
39	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. <i>Current Opinion in Urology</i> , 2020, 30, 457-466.	0.9	2
40	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146
41	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2367.	1.8	34
42	Bempegaldesleukin (BEMPEG ; NKTR 214) efficacy as a single agent and in combination with checkpoint inhibitor therapy in mouse models of osteosarcoma. <i>International Journal of Cancer</i> , 2021, 148, 1928-1937.	2.3	8
43	Engineering IL-2 to Give New Life to T Cell Immunotherapy. <i>Annual Review of Medicine</i> , 2021, 72, 281-311.	5.0	72
45	Improving safety of cancer immunotherapy via delivery technology. <i>Biomaterials</i> , 2021, 265, 120407.	5.7	22
46	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021, 17, 137-149.	1.1	5
47	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet, The</i> , 2021, 397, 1010-1022.	6.3	196
48	Arrested development: suppression of NK cell function in the tumor microenvironment. <i>Clinical and Translational Immunology</i> , 2021, 10, e1238.	1.7	36
49	NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100103.	2.0	32
50	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	15.2	357
51	The evolving landscape of immunotherapy in solid tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 798-806.	0.8	17
52	Utilizing Immunocytokines for Cancer Therapy. <i>Antibodies</i> , 2021, 10, 10.	1.2	24
53	Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002214.	3.9	19
54	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 653358.	2.2	19
55	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	1.7	50

#	ARTICLE	IF	CITATIONS
56	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opinion on Emerging Drugs, 2021, 26, 79-92.	1.0	13
57	MHC heterogeneity and response of metastases to immunotherapy. Cancer and Metastasis Reviews, 2021, 40, 501-517.	2.7	12
58	Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers. Clinical and Translational Oncology, 2021, 23, 1979-1994.	1.2	18
59	Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress. Advanced Therapeutics, 2021, 4, 2100035.	1.6	42
60	Next-generation cytokines for cancer immunotherapy. Antibody Therapeutics, 2021, 4, 123-133.	1.2	26
61	Modeling cell-specific dynamics and regulation of the common gamma chain cytokines. Cell Reports, 2021, 35, 109044.	2.9	13
62	Combination of Beppegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 645352.	1.3	2
63	Strategies to sensitize cancer cells to immunotherapy. Human Vaccines and Immunotherapeutics, 2021, 17, 2595-2601.	1.4	9
64	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nature Communications, 2021, 12, 2768.	5.8	62
65	Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Frontiers in Immunology, 2021, 12, 674400.	2.2	22
66	Cytokines in the Treatment of Melanoma. Current Oncology Reports, 2021, 23, 83.	1.8	17
67	Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227.	3.4	42
68	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?. Expert Opinion on Biological Therapy, 2021, 21, 1347-1357.	1.4	14
69	From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Advanced Materials, 2021, 33, e2008094.	11.1	60
70	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology, 2021, 18, 558-576.	12.5	202
71	Combination of radiation therapy, bempedaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. , 2021, 9, e002715.		26
72	Switching on prodrugs using radiotherapy. Nature Chemistry, 2021, 13, 805-810.	6.6	91
73	Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 2021, 21, 481-499.	12.8	318

#	ARTICLE	IF	CITATIONS
74	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707198.	1.8	17
75	SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1508-1520.	1.9	8
77	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 1141-1157.	1.6	33
78	Next-Generation Immunotherapy Approaches in Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 116.	1.8	3
79	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	0.8	55
80	Interleukin-2 therapy of cancer-clinical perspectives. <i>International Immunopharmacology</i> , 2021, 98, 107836.	1.7	37
81	Clinical translation of immunomodulatory therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113896.	6.6	8
82	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
83	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. <i>Cancers</i> , 2021, 13, 373.	1.7	18
84	Cytokine Receptors. , 2021, , .		1
85	Immune Therapy: What Can We Learn From Acquired Resistance?. <i>Current Cancer Research</i> , 2021, , 75-114.	0.2	0
86	Adoptive NK cell therapies in children with cancer: Clinical challenges and future possibilities. , 2021, , 405-437.		0
87	Overview of Basic Immunology and Clinical Application. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 1-36.	0.8	8
88	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 51-68.	0.8	41
89	Chemo-physical Strategies to Advance the <i>in Vivo</i> Functionality of Targeted Nanomedicine: The Next Generation. <i>Journal of the American Chemical Society</i> , 2021, 143, 538-559.	6.6	148
90	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	1.9	162
91	Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	4
95	Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. , 2020, 8, e001591.		6

#	ARTICLE	IF	CITATIONS
96	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	7.7	158
97	A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties <i>in vivo</i> . <i>Oncotarget</i> , 2020, 11, 3698-3711.	0.8	8
98	Combination drug regimens for metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2020, 11, 541-562.	0.9	19
99	Role of Immunotherapy in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 479-489.	2.3	295
100	Quantification of natural abundance NMR data differentiates the solution behavior of monoclonal antibodies and their fragments. <i>MABs</i> , 2021, 13, 1978132.	2.6	0
102	Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2020, 7, 17-26.	0.2	7
103	CHAPTER 14. Cell and Immune Therapy. <i>RSC Detection Science</i> , 2020, , 303-344.	0.0	0
104	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	12
105	Immunotherapy for Pediatric Sarcomas. <i>Pediatric Oncology</i> , 2021, , 165-180.	0.5	0
106	Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion. , 2021, 9, e003480.		4
107	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7
108	Immune System in Action. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 1-43.	0.8	0
110	The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 95-104.	1.9	3
111	Harnessing cytokines and chemokines for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 237-253.	12.5	305
112	PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	1.1	7
113	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
114	Engineering interferons and interleukins for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114112.	6.6	54
115	Natural Killer Cell-targeted Immunotherapy for Cancer. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 513-526.	0.6	4

#	ARTICLE	IF	CITATIONS
116	Interleukins in the treatment of melanoma. Chinese Medical Journal, 2022, 135, 393-399.	0.9	4
117	The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective. Biomedicines, 2022, 10, 251.	1.4	13
118	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clinical Genitourinary Cancer, 2022, 20, 252-259.	0.9	4
119	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer. Current Oncology, 2022, 29, 38-55.	0.9	7
120	Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy. Immune Network, 2022, 22, e5.	1.6	11
121	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics, 2022, 14, 397.	2.0	4
122	An anti-PD-1>R-L bispecific agonist induces GTR clustering-mediated T cell activation for cancer immunotherapy. Nature Cancer, 2022, 3, 337-354.	5.7	41
123	Advancement of cancer immunotherapy using nanoparticles-based nanomedicine. Seminars in Cancer Biology, 2022, 86, 624-644.	4.3	41
124	Natural killer cell therapy: A new frontier for obesity-associated cancer. Cancer Letters, 2022, 535, 215620.	3.2	17
125	Neue Strategien für die onkologische Therapie: Interleukine im Fokus. , 0, , .		0
126	A quantitative view of strategies to engineer cell-selective ligand binding. Integrative Biology (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	5
127	Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. International Journal of Molecular Sciences, 2022, 23, 164.	1.8	14
128	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
129	Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Frontiers in Immunology, 2022, 13, 872010.	2.2	23
130	Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8⁺ T cell cytotoxicity over BEMPEG+RT. , 2022, 10, e004218.		12
131	Double Trouble: Immunotherapy Doublets in Melanoma& Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 745-766.	1.8	6
132	Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nature Reviews Immunology, 2023, 23, 90-105.	10.6	110
133	Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. European Urology, 2022, 82, 365-373.	0.9	6

#	ARTICLE	IF	CITATIONS
134	Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	5
135	Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 673-686.	1.8	3
136	Pilot study of bempregaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	21
137	NK Cell-Based Immunotherapy in Colorectal Cancer. <i>Vaccines</i> , 2022, 10, 1033.	2.1	10
138	Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
139	Advances in Diagnosis and Therapy for Bladder Cancer. <i>Cancers</i> , 2022, 14, 3181.	1.7	16
140	Enhancing adoptive T cell therapy with fucoidan-based IL-2 delivery microcapsules. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	4
141	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
142	Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. <i>Cancer Letters</i> , 2022, 547, 215887.	3.2	24
143	Signaling new therapeutic opportunities: cytokines in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1233-1243.	1.4	2
144	PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. <i>Nature</i> , 2022, 610, 161-172.	13.7	81
145	Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells. <i>Pharmaceutics</i> , 2022, 14, 2040.	2.0	1
146	Novel Therapies in Clinical Development for Advanced Disease. , 0, , .		0
147	Targeting the IL-2 pathway for the treatment of mucosal melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2022, 10, 34-47.	0.5	0
148	Interleukin-2-based therapies in cancer. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	21
149	Designing Cancer Immunotherapies That Engage T Cells and NK Cells. <i>Annual Review of Immunology</i> , 2023, 41, 17-38.	9.5	30
150	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. <i>Medical Alphabet</i> , 2022, , 35-40.	0.0	2
151	Immunogenic change after percutaneous microwave ablation in pulmonary malignancies: Variation in immune cell subsets and cytokines in peripheral blood. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
153	Adoptive Cell Transfer for Solid Tumors. , 2023, , .		1
154	Tumor immunology. , 2023, , 245-452.		0
155	Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. , 2023, 11, e006346.		8
156	Phytochemicals as Immunomodulatory Agents in Melanoma. International Journal of Molecular Sciences, 2023, 24, 2657.	1.8	4
157	Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications. , 2023, , 335-367.		1
158	New Therapies on the Horizon. Hematology/Oncology Clinics of North America, 2023, , .	0.9	1
159	Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer Immunology, Immunotherapy, 0, , .	2.0	0
160	The application of Interleukin-2 family cytokines in tumor immunotherapy research. Frontiers in Immunology, 0, 14, .	2.2	6
161	Melanoma and immunotherapy: the experience of Sapienza University of Rome. Italian Journal of Dermatology and Venereology, 2023, 158, .	0.1	0
162	A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine, 2023, 90, 104539.	2.7	29
163	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
164	Low Expression of TSTD2 Serves as a Biomarker for Poor Prognosis in Kidney Renal Clear Cell Carcinoma. International Journal of General Medicine, 0, Volume 16, 1437-1453.	0.8	0
170	Potential of Biotechnology in Cancer Management. , 2023, , 9-44.		0
173	Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases. BioDrugs, 2024, 38, 227-248.	2.2	1